{"id":"recombinant-influenza-vaccines","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site pain or erythema"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"1-5","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL5315104","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These vaccines use recombinant hemagglutinin (HA) or other influenza surface antigens manufactured in cell culture or insect cells rather than grown in eggs or cultured virus. This approach allows for rapid production, reduced egg-dependency, and potentially improved immunogenicity. The recombinant antigens trigger both humoral and cellular immune responses to provide protection against seasonal influenza infection.","oneSentence":"Recombinant influenza vaccines stimulate the immune system to produce antibodies and cellular immunity against influenza virus antigens produced through recombinant DNA technology.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:04:17.803Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults"},{"name":"Seasonal influenza prevention in pediatric populations"}]},"trialDetails":[{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT07110532","phase":"PHASE1","title":"pH1N1 Blinded Challenge Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-10","conditions":"Influenza","enrollment":180},{"nctId":"NCT07291635","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine","status":"RECRUITING","sponsor":"Aramis Biotechnologies Inc.","startDate":"2026-02-25","conditions":"Influenza","enrollment":728},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT06850051","phase":"PHASE1","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-03-19","conditions":"Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination","enrollment":270},{"nctId":"NCT07287137","phase":"PHASE4","title":"Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2025-11-12","conditions":"COVID -19, COVID - 19, COVID 19","enrollment":54},{"nctId":"NCT05569239","phase":"PHASE2","title":"Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg","status":"ACTIVE_NOT_RECRUITING","sponsor":"Osivax","startDate":"2025-09-08","conditions":"Influenza","enrollment":2850},{"nctId":"NCT02872311","phase":"NA","title":"Open-Label Influenza Vaccine Evaluation","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2016-09","conditions":"Immune Response","enrollment":179},{"nctId":"NCT07240922","phase":"PHASE4","title":"The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-10-01","conditions":"Influenza","enrollment":600},{"nctId":"NCT06694389","phase":"PHASE3","title":"Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-11-18","conditions":"COVID-19, Influenza","enrollment":2457},{"nctId":"NCT03598439","phase":"PHASE4","title":"Randomized Influenza Vaccine Evaluation of Immune Response","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2018-07-30","conditions":"Influenza","enrollment":366},{"nctId":"NCT05479370","phase":"PHASE3","title":"Immunogenicity Trial of 3 Influenza Vaccines","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2022-09-29","conditions":"Influenza Vaccination","enrollment":366},{"nctId":"NCT06605625","phase":"","title":"Vaccine Responses in Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2022-11-04","conditions":"Viral Vaccines","enrollment":250},{"nctId":"NCT03945825","phase":"PHASE1","title":"Flublok or Fluzone With Advax-CpG55.2 or AF03","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-06-10","conditions":"Influenza, Influenza Immunisation","enrollment":241},{"nctId":"NCT06237049","phase":"PHASE2","title":"A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-01-31","conditions":"Influenza, Human, SARS-CoV-2 Infection, COVID-19","enrollment":644},{"nctId":"NCT06355232","phase":"PHASE1","title":"Covid-19 and Influenza Oral Vaccine Study","status":"RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2024-05-01","conditions":"covid19 Infection, Influenza, Human","enrollment":100},{"nctId":"NCT04451954","phase":"PHASE1","title":"Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-07-02","conditions":"Influenza Immunisation, Healthy Volunteers","enrollment":210},{"nctId":"NCT05829356","phase":"PHASE1","title":"Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-04-12","conditions":"Influenza Immunization","enrollment":159},{"nctId":"NCT04969276","phase":"PHASE2","title":"Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-07-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":306},{"nctId":"NCT05144945","phase":"PHASE3","title":"Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-12-07","conditions":"Influenza (Healthy Volunteers)","enrollment":301},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT05513053","phase":"PHASE3","title":"Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-10-27","conditions":"Influenza Immunization","enrollment":1308},{"nctId":"NCT05513391","phase":"PHASE3","title":"Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-10","conditions":"Influenza Immunization","enrollment":366},{"nctId":"NCT04978454","phase":"PHASE1","title":"Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-19","conditions":"Influenza","enrollment":60},{"nctId":"NCT04144179","phase":"PHASE1","title":"Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-11-06","conditions":"Influenza","enrollment":150},{"nctId":"NCT06361875","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-04-01","conditions":"Influenza Immunization","enrollment":910},{"nctId":"NCT06972810","phase":"NA","title":"Human Infection Study of H3N2 Influenza in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2025-05-05","conditions":"Influenza","enrollment":12},{"nctId":"NCT06582277","phase":"PHASE2","title":"Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836","status":"COMPLETED","sponsor":"Osivax","startDate":"2024-10-22","conditions":"Vaccine-Preventable Diseases, Influenza","enrollment":117},{"nctId":"NCT06695130","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-18","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT04583995","phase":"PHASE3","title":"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","status":"COMPLETED","sponsor":"Novavax","startDate":"2020-09-28","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":15185},{"nctId":"NCT06015282","phase":"PHASE3","title":"The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-11-03","conditions":"Influenza, Human","enrollment":7741},{"nctId":"NCT03694392","phase":"","title":"Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2018-09-16","conditions":"Influenza, Pneumonia, Lower Respiratory Tract Infection","enrollment":2776278},{"nctId":"NCT06695117","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-19","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT05514002","phase":"PHASE4","title":"Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years","status":"TERMINATED","sponsor":"Fatimah Dawood","startDate":"2022-09-13","conditions":"Influenza, Human","enrollment":3988},{"nctId":"NCT06890429","phase":"PHASE2","title":"Phase 2 Study of the RSV/Flu-01E Vaccine Against Respiratory Syncytial Virus Infection in Older Adults","status":"COMPLETED","sponsor":"Research Institute of Influenza, Russia","startDate":"2023-12-07","conditions":"Respiratory Synctial Virus Infections","enrollment":120},{"nctId":"NCT06873282","phase":"PHASE2","title":"Phase 2 Study of the ТВ/Flu-05Е Tuberculosis Vaccine","status":"COMPLETED","sponsor":"Research Institute of Influenza, Russia","startDate":"2023-12-13","conditions":"Tuberculosis","enrollment":160},{"nctId":"NCT05650554","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-12-12","conditions":"Influenza Immunization","enrollment":682},{"nctId":"NCT05624606","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-28","conditions":"Influenza Immunization","enrollment":682},{"nctId":"NCT06476275","phase":"PHASE1","title":"Single Dose Texas 2017 (H3N2) Challenge Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-11","conditions":"Influenza Viral Infections","enrollment":33},{"nctId":"NCT06765187","phase":"","title":"Cross-sectional Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Between 18 and 64 Years Old Using the Vaccinees Perception of Injection","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-18","conditions":"Influenza Immunization, Health Volunteers","enrollment":447},{"nctId":"NCT05553301","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-10-03","conditions":"Influenza Immunization","enrollment":560},{"nctId":"NCT06130345","phase":"","title":"Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2","enrollment":15196685},{"nctId":"NCT05284799","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.","status":"COMPLETED","sponsor":"Osivax","startDate":"2022-05-09","conditions":"Influenza","enrollment":180},{"nctId":"NCT05858450","phase":"","title":"This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-05-05","conditions":"Influenza, Human, COVID-19","enrollment":3442996},{"nctId":"NCT05397119","phase":"PHASE1","title":"A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"BlueWillow Biologics","startDate":"2022-07-07","conditions":"Influenza, Pandemic","enrollment":40},{"nctId":"NCT03722589","phase":"PHASE4","title":"Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2018-09-12","conditions":"Influenza","enrollment":944},{"nctId":"NCT05007041","phase":"PHASE4","title":"Simultaneous RZV and aIIV4 Vaccination","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-09-21","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":267},{"nctId":"NCT05310084","phase":"PHASE3","title":"Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-04-20","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":1134},{"nctId":"NCT05945498","phase":"PHASE1","title":"Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years","status":"COMPLETED","sponsor":"Tatyana Zubkova","startDate":"2023-05-10","conditions":"Tuberculosis Infection","enrollment":51},{"nctId":"NCT05696067","phase":"PHASE1, PHASE2","title":"Evaluation of Corfluvec Vaccine for the Prevention of COVID-19 in Healthy Volunteers","status":"COMPLETED","sponsor":"Tatyana Zubkova","startDate":"2022-09-13","conditions":"COVID-19","enrollment":200},{"nctId":"NCT05970744","phase":"PHASE1","title":"Evaluation of RSV/Flu-01E Vaccine for the Prevention of RSV Infection in Volunteers Aged 18 to 59 Years and Over 60 Years","status":"COMPLETED","sponsor":"Tatyana Zubkova","startDate":"2023-05-10","conditions":"Respiratory Syncytial Virus Infections","enrollment":60},{"nctId":"NCT04576702","phase":"PHASE2","title":"Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2020-10-08","conditions":"Influenza, Human","enrollment":471},{"nctId":"NCT05028361","phase":"PHASE4","title":"Simultaneous mRNA COVID-19 and IIV4 Vaccination Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-10-04","conditions":"Quality of Life, Injection Site Reaction, Adverse Drug Event","enrollment":348},{"nctId":"NCT01006798","phase":"PHASE1","title":"Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2009-10","conditions":"Bird Flu, Influenza","enrollment":166},{"nctId":"NCT05781191","phase":"","title":"Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-11-13","conditions":"Influenza, COVID-19","enrollment":8231},{"nctId":"NCT05375838","phase":"PHASE1, PHASE2","title":"A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-13","conditions":"SARS-CoV-2, Influenza","enrollment":550},{"nctId":"NCT05409612","phase":"PHASE3","title":"Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-11-07","conditions":"Morbid Obesity, Severe Obesity","enrollment":206},{"nctId":"NCT05734040","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.","status":"COMPLETED","sponsor":"Osivax","startDate":"2023-05-10","conditions":"Influenza","enrollment":478},{"nctId":"NCT04576377","phase":"PHASE4","title":"Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2020-10-05","conditions":"Influenza, Human","enrollment":977},{"nctId":"NCT03330132","phase":"PHASE4","title":"Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2017-10-07","conditions":"Influenza, Human","enrollment":1861},{"nctId":"NCT03734237","phase":"PHASE4","title":"A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD","status":"UNKNOWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2018-11-06","conditions":"Influenza, Influenza-like Illness, Influenza Vaccines","enrollment":15449},{"nctId":"NCT04523324","phase":"PHASE4","title":"Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2019-10-31","conditions":"Influenza","enrollment":577},{"nctId":"NCT05047770","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-07","conditions":"Herpes Zoster","enrollment":2013},{"nctId":"NCT06118151","phase":"PHASE1","title":"Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-04-11","conditions":"Influenza, Influenza Immunization","enrollment":388},{"nctId":"NCT05060887","phase":"PHASE2","title":"Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.","status":"COMPLETED","sponsor":"Osivax","startDate":"2021-11-15","conditions":"Influenza","enrollment":239},{"nctId":"NCT04622592","phase":"PHASE1, PHASE2","title":"Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Medicago","startDate":"2020-11-02","conditions":"Influenza","enrollment":209},{"nctId":"NCT04695717","phase":"PHASE3","title":"This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2020-09-05","conditions":"Influenza","enrollment":864},{"nctId":"NCT05107375","phase":"PHASE3","title":"Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2021-09-03","conditions":"Coronavirus Disease 2019","enrollment":299},{"nctId":"NCT04120194","phase":"PHASE3","title":"Phase 3 Pivotal Trial of NanoFlu™ in Older Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2019-10-14","conditions":"Influenza, Human","enrollment":2654},{"nctId":"NCT03965195","phase":"PHASE4","title":"Recombinant Influenza Vaccination in U.S. Nursing Homes","status":"UNKNOWN","sponsor":"Insight Therapeutics, LLC","startDate":"2019-07-20","conditions":"Influenza, Influenza -Like Illness, Influenza, Human","enrollment":1989},{"nctId":"NCT03969641","phase":"PHASE4","title":"Safety of RIV4 Versus IIV4 in Pregnant Women","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-09-05","conditions":"Safety, Adverse Event Following Immunisation, Birth Outcomes","enrollment":384},{"nctId":"NCT03293498","phase":"PHASE1, PHASE2","title":"Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)","status":"COMPLETED","sponsor":"Novavax","startDate":"2017-09-18","conditions":"Influenza","enrollment":330},{"nctId":"NCT03658629","phase":"PHASE2","title":"Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults","status":"TERMINATED","sponsor":"Novavax","startDate":"2018-09-24","conditions":"Influenza, Human","enrollment":1375},{"nctId":"NCT04192500","phase":"PHASE2","title":"Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years","status":"COMPLETED","sponsor":"Osivax","startDate":"2019-12-11","conditions":"Influenza","enrollment":300},{"nctId":"NCT03594890","phase":"PHASE1","title":"Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects","status":"COMPLETED","sponsor":"Osivax","startDate":"2018-06-12","conditions":"Influenza","enrollment":72},{"nctId":"NCT04077424","phase":"PHASE4","title":"Senescent Immunity in Elders and Vaccine Responses (SILVER)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-10-21","conditions":"Flu Vaccine","enrollment":10},{"nctId":"NCT04833101","phase":"PHASE4","title":"Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-04-07","conditions":"COVID-19","enrollment":120},{"nctId":"NCT00539981","phase":"PHASE3","title":"Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09-15","conditions":"Influenza","enrollment":4648},{"nctId":"NCT03450915","phase":"PHASE3","title":"A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2018-08-01","conditions":"Influenza","enrollment":12460},{"nctId":"NCT02501421","phase":"PHASE1","title":"Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine","status":"COMPLETED","sponsor":"Research Institute for Biological Safety Problems","startDate":"2013-10","conditions":"Tuberculosis","enrollment":44},{"nctId":"NCT04034290","phase":"PHASE2","title":"A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac","status":"COMPLETED","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","startDate":"2019-10-18","conditions":"Healthy Volunteers","enrollment":224},{"nctId":"NCT03058692","phase":"PHASE2","title":"Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-04-09","conditions":"Influenza, Influenza Immunisation","enrollment":120},{"nctId":"NCT03283319","phase":"PHASE2","title":"Panblok H7 Vaccine Adjuvanted With AS03 or MF59","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2017-09-20","conditions":"Influenza, Human","enrollment":366},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT02206464","phase":"PHASE1","title":"H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-07-29","conditions":"Influenza","enrollment":30},{"nctId":"NCT03460743","phase":"PHASE3","title":"Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.","status":"COMPLETED","sponsor":"Laboratorios Liomont","startDate":"2018-03-22","conditions":"Influenza, Human","enrollment":1556},{"nctId":"NCT02335164","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Vaxine Pty Ltd","startDate":"2015-07","conditions":"Influenza","enrollment":270},{"nctId":"NCT03038776","phase":"PHASE1","title":"Recombinant H7 Hemagglutinin Influenza Vaccine Trial","status":"COMPLETED","sponsor":"Vaxine Pty Ltd","startDate":"2017-01","conditions":"Influenza, Avian","enrollment":150},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT03651544","phase":"PHASE1","title":"The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac","status":"COMPLETED","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","startDate":"2018-10-15","conditions":"Influenza A Virus Infection, Influenza A, Influenza Epidemic","enrollment":36},{"nctId":"NCT03146403","phase":"PHASE2","title":"Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection","status":"TERMINATED","sponsor":"Genocea Biosciences, Inc.","startDate":"2017-05-24","conditions":"Genital Herpes, HSV-2 Infection","enrollment":33},{"nctId":"NCT03789539","phase":"PHASE1","title":"Reactogenicity, Safety and Immunogenicity of an Universal Influenza Vaccine Uniflu","status":"UNKNOWN","sponsor":"VA Pharma Limited Liability Company","startDate":"2018-06-02","conditions":"Safety Issues","enrollment":54},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT02957656","phase":"PHASE1","title":"Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12","conditions":"Influenza A Virus, H7N9 Subtype","enrollment":53},{"nctId":"NCT02515175","phase":"PHASE2","title":"Evaluating New Formulation of Therapeutic HSV-2 Vaccine","status":"COMPLETED","sponsor":"Genocea Biosciences, Inc.","startDate":"2015-11","conditions":"Genital Herpes Simplex Type 2","enrollment":131},{"nctId":"NCT02883426","phase":"PHASE1","title":"Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09","conditions":"Influenza","enrollment":1},{"nctId":"NCT02691130","phase":"PHASE2","title":"Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2015-11","conditions":"Influenza, Healthy","enrollment":224},{"nctId":"NCT02285998","phase":"PHASE3","title":"Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2014-10","conditions":"Influenza","enrollment":9003},{"nctId":"NCT02464163","phase":"PHASE1, PHASE2","title":"Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2015-07","conditions":"Influenza","enrollment":407}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Recombinant influenza vaccines","genericName":"Recombinant influenza vaccines","companyName":"Henry M. Jackson Foundation for the Advancement of Military Medicine","companyId":"henry-m-jackson-foundation-for-the-advancement-of-military-medicine","modality":"Biologic","firstApprovalDate":"","aiSummary":"Recombinant influenza vaccines stimulate the immune system to produce antibodies and cellular immunity against influenza virus antigens produced through recombinant DNA technology. Used for Seasonal influenza prevention in adults, Seasonal influenza prevention in pediatric populations.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}